- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03259269
Expand New Drugs for TB [endTB]
June 9, 2022 updated by: Partners in Health
endTB (Expand New Drugs for TB) Observational Study: Treatment of MDR-TB With Regimens Containing Bedaquiline or Delamanid
This observational study will examine the safety and efficacy of bedaquiline and delamanid used (individually, not together) in routine, multidrug regimens for treatment of MDR-TB.
The information gathered in this study will inform doctors how best to use these TB drugs in the future.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Observational
Enrollment (Actual)
2804
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Abovyan, Armenia
- National Treatment Centre for Tuberculosis, Abovian, Armenia
-
-
-
-
-
Dhaka, Bangladesh
- National Institute of Diseases of the Chest and Hospital (NIDCH), Dhaka
-
-
-
-
-
Minsk, Belarus, 220053
- Republican Research and Practical Centre for Pulmonology and Tuberculosis
-
-
-
-
-
Bishoftu, Ethiopia
- Bishoftu hospital
-
-
-
-
-
Tbilisi, Georgia, 0101
- National Center for Tuberculosis and Lung Diseases
-
-
-
-
-
Jakarta, Indonesia
- RS Islam Jakarta Cempaka Putih
-
-
-
-
-
Almaty, Kazakhstan, 050010
- National Research Center for Phthisionpulmonology
-
-
-
-
-
Nairobi, Kenya
- MSF Tuberculosis clinic, Mathare, Nairobi, Kenya
-
-
-
-
-
Kara-Suu, Kyrgyzstan
- Kara-Suu District TB hospital
-
-
-
-
-
Maseru, Lesotho
- Botshabelo Hospital
-
-
-
-
-
Yangon, Myanmar
- Aung San Tuberculosis Hospital
-
-
-
-
-
Karachi, Pakistan
- The Indus Hospital, Karachi
-
Kotri, Pakistan
- Institute of Chest Diseases, Kotri
-
Lahore, Pakistan
- Gulab Devi Chest Hospital, Lahore
-
-
-
-
-
Carabayllo, Peru
- Socios En Salud
-
-
-
-
-
Durban, South Africa
- King Dinuzulu Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Non-Probability Sample
Study Population
All MDR-TB patients started on treatment containing a new TB drug (bedaquiline or delamanid) and enrolled in clinical care within the endTB Project.
Description
Inclusion Criteria:
- Any patient who receives a treatment regimen containing bedaquiline or delamanid at an endTB site will be invited to participate in this observational study, regardless of age or gender.
- Any patient who signs the study informed consent form will be included in the study.
Exclusion Criteria:
- Refusal to participate in the study.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Bedaquiline and companion WHO Group 5 drugs
|
No applicable intervention; this is a secondary data analysis observational study.
|
Delamanid and companion WHO Group 5 drugs
|
No applicable intervention; this is a secondary data analysis observational study.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
End of treatment outcome
Time Frame: 20 - 24 months of treatment
|
Final outcomes: cured, treatment completed, treatment failed, lost to follow-up, died, not evaluated
|
20 - 24 months of treatment
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Huerga H, Khan U, Bastard M, Mitnick CD, Lachenal N, Khan PY, Seung KJ, Melikyan N, Ahmed S, Rich ML, Varaine F, Osso E, Rashitov M, Salahuddin N, Salia G, Sanchez E, Serobyan A, Rafi Siddiqui M, Grium Tefera D, Vetushko D, Yeghiazaryan L, Holtzman D, Islam S, Kumsa A, Jacques Leblanc G, Leonovich O, Mamsa S, Manzur-Ul-Alam M, Myint Z, Padayachee S, Franke MF, Hewison C. Safety and Effectiveness Outcomes From a 14-Country Cohort of Patients With Multi-Drug Resistant Tuberculosis Treated Concomitantly With Bedaquiline, Delamanid, and Other Second-Line Drugs. Clin Infect Dis. 2022 Oct 12;75(8):1307-1314. doi: 10.1093/cid/ciac176.
- Hewison C, Khan U, Bastard M, Lachenal N, Coutisson S, Osso E, Ahmed S, Khan P, Franke MF, Rich ML, Varaine F, Melikyan N, Seung KJ, Adenov M, Adnan S, Danielyan N, Islam S, Janmohamed A, Karakozian H, Kamene Kimenye M, Kirakosyan O, Kholikulov B, Krisnanda A, Kumsa A, Leblanc G, Lecca L, Nkuebe M, Mamsa S, Padayachee S, Thit P, Mitnick CD, Huerga H. Safety of Treatment Regimens Containing Bedaquiline and Delamanid in the endTB Cohort. Clin Infect Dis. 2022 Sep 29;75(6):1006-1013. doi: 10.1093/cid/ciac019. Erratum In: Clin Infect Dis. 2023 Jan 13;:
- Khan PY, Franke MF, Hewison C, Seung KJ, Huerga H, Atwood S, Ahmed S, Khan M, Sultana T, Manzur-Ul-Alam M, Vo LNQ, Lecca L, Yae K, Kozhabekov S, Tamirat M, Gelin A, Vilbrun SC, Kikvidze M, Faqirzai J, Kadyrov A, Skrahina A, Mesic A, Avagyan N, Bastard M, Rich ML, Khan U, Mitnick CD. All-oral longer regimens are effective for the management of multidrug-resistant tuberculosis in high-burden settings. Eur Respir J. 2022 Jan 20;59(1):2004345. doi: 10.1183/13993003.04345-2020. Print 2022 Jan.
- Maretbayeva SM, Rakisheva AS, Adenov MM, Yeraliyeva LT, Algozhin YZ, Stambekova AT, Berikova EA, Yedilbayev A, Rich ML, Seung KJ, Issayeva AM. Culture conversion at six months in patients receiving bedaquiline- and delamanid-containing regimens for the treatment of multidrug-resistant tuberculosis. Int J Infect Dis. 2021 Dec;113 Suppl 1:S91-S95. doi: 10.1016/j.ijid.2021.03.075. Epub 2021 Apr 3. Erratum In: Int J Infect Dis. 2022 Aug;121:105.
- Franke MF, Khan P, Hewison C, Khan U, Huerga H, Seung KJ, Rich ML, Zarli K, Samieva N, Oyewusi L, Nair P, Mudassar M, Melikyan N, Lenggogeni P, Lecca L, Kumsa A, Khan M, Islam S, Hussein K, Docteur W, Chumburidze N, Berikova E, Atshemyan H, Atwood S, Alam M, Ahmed S, Bastard M, Mitnick CD. Culture Conversion in Patients Treated with Bedaquiline and/or Delamanid. A Prospective Multicountry Study. Am J Respir Crit Care Med. 2021 Jan 1;203(1):111-119. doi: 10.1164/rccm.202001-0135OC. Erratum In: Am J Respir Crit Care Med. 2021 Apr 1;203(7):929. Am J Respir Crit Care Med. 2022 Jul 15;206(2):231.
- Seung KJ, Franke MF, Hewison C, Huerga H, Khan U, Mitnick CD; end TB Study Group. High prevalence of hepatitis C infection among multidrug-resistant tuberculosis patients. J Hepatol. 2020 May;72(5):1028-1029. doi: 10.1016/j.jhep.2019.10.018. Epub 2020 Mar 6. No abstract available. Erratum In: J Hepatol. 2022 Aug;77(2):583.
- Seung KJ, Khan P, Franke MF, Ahmed S, Aiylchiev S, Alam M, Putri FA, Bastard M, Docteur W, Gottlieb G, Hewison C, Islam S, Khachatryan N, Kotrikadze T, Khan U, Kumsa A, Lecca L, Tassew YM, Melikyan N, Naing YY, Oyewusi L, Rich M, Wanjala S, Yedilbayev A, Huerga H, Mitnick CD. Culture Conversion at 6 Months in Patients Receiving Delamanid-containing Regimens for the Treatment of Multidrug-resistant Tuberculosis. Clin Infect Dis. 2020 Jul 11;71(2):415-418. doi: 10.1093/cid/ciz1084. Erratum In: Clin Infect Dis. 2023 Jan 13;76(2):374.
- Khan U, Huerga H, Khan AJ, Mitnick CD, Hewison C, Varaine F, Bastard M, Rich M, Franke MF, Atwood S, Khan PY, Seung KJ. The endTB observational study protocol: treatment of MDR-TB with bedaquiline or delamanid containing regimens. BMC Infect Dis. 2019 Aug 20;19(1):733. doi: 10.1186/s12879-019-4378-4.
- Lachenal N, Hewison C, Mitnick C, Lomtadze N, Coutisson S, Osso E, Ahmed S, Leblanc G, Islam S, Atshemyan H, Nair P, Kholikulov B, Aiylchiev S, Zarli K, Adnan S, Krisnanda A, Padayachee S, Stambekova A, Sahabutdinova Y, de Guadalupe S, Moreno P, Kumsa A, Reshid A, Makaka J, Abebe S, Melikyan N, Seung KJ, Khan U, Khan P, Huerga H, Rich M, Varaine F. Setting up pharmacovigilance based on available endTB Project data for bedaquiline. Int J Tuberc Lung Dis. 2020 Oct 1;24(10):1087-1094. doi: 10.5588/ijtld.20.0115.
- Seung KJ, Khan U, Varaine F, Ahmed S, Bastard M, Cloez S, Damtew D, Franke MF, Herboczek K, Huerga H, Islam S, Karakozian H, Khachatryan N, Kliesckova J, Khan AJ, Khan M, Khan P, Kotrikadze T, Lachenal N, Lecca L, Lenggogeni P, Maretbayeva S, Melikyan N, Mesic A, Mitnick CD, Mofolo M, Perrin C, Richard M, Tassew YM, Telnov A, Vilbrun SC, Wanjala S, Rich ML, Hewison C. Introducing new and repurposed TB drugs: the endTB experience. Int J Tuberc Lung Dis. 2020 Oct 1;24(10):1081-1086. doi: 10.5588/ijtld.20.0141.
Helpful Links
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
April 1, 2015
Primary Completion (Actual)
September 30, 2019
Study Completion (Actual)
December 30, 2019
Study Registration Dates
First Submitted
August 21, 2017
First Submitted That Met QC Criteria
August 21, 2017
First Posted (Actual)
August 23, 2017
Study Record Updates
Last Update Posted (Actual)
June 13, 2022
Last Update Submitted That Met QC Criteria
June 9, 2022
Last Verified
June 1, 2022
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- Partners IRB 2015P001669
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Tuberculosis, Multidrug-Resistant
-
Otsuka Pharmaceutical Development & Commercialization...CompletedMultidrug-resistant TuberculosisSouth Africa, Estonia, Philippines, Peru, Lithuania, Latvia, Moldova, Republic of
-
Janssen Research & Development, LLCRecruitingMultidrug-Resistant TuberculosisMozambique, Philippines, Russian Federation, South Africa, Uganda, Ukraine
-
University of Cape TownBaylor Research InstituteCompletedMultidrug-resistant TuberculosisSouth Africa
-
University of Cape TownUniversity of Stellenbosch; University of Cape Town Lung Institute; University... and other collaboratorsCompletedTuberculosis | Multidrug Resistant Tuberculosis | Extensively-drug Resistant TuberculosisSouth Africa
-
University Medical Center GroningenCompletedMultidrug-resistant Tuberculosis | Extensively Drug-resistant TuberculosisNetherlands
-
Foundation for Innovative New Diagnostics, SwitzerlandInstitute of Tropical Medicine, Belgium; Research Center Borstel; National Institute...CompletedMultidrug-Resistant Tuberculosis | Isoniazid Resistant Pulmonary Tuberculosis | Rifampicin Resistant Tuberculosis | Pulmonary Tuberculoses
-
National Institute of Allergy and Infectious Diseases...Eunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaboratorsRecruitingTuberculosis, MDRHaiti, Tanzania, Thailand, Botswana, Brazil, India, Kenya, Peru, Philippines, South Africa, Uganda, Zimbabwe, Vietnam
-
Otsuka Pharmaceutical Development & Commercialization...TerminatedTuberculosisLatvia, Lithuania
-
Otsuka Pharmaceutical Development & Commercialization...CompletedMultidrug Resistant TuberculosisPhilippines, South Africa
-
Huashan HospitalUnknownMultidrug Resistant TuberculosisChina
Clinical Trials on This is a non-intervention observational study
-
University of Colorado, DenverNational Institute on Drug Abuse (NIDA)CompletedThe Influence of in Utero Cannabis Exposure on Neonatal Brain Morphology and Structural ConnectivityDrug Use | Neurodevelopmental Abnormality | Cannabis Use Disorder | PREG1 | Fetal Exposure During PregnancyUnited States
-
Medlior Health Outcomes Research LtdCompletedChronic Kidney Diseases | Type 2 Diabetes
-
Huashan HospitalRecruitingMultidrug Resistant TuberculosisChina
-
Shanghai Zhongshan HospitalNot yet recruiting
-
Novartis VaccinesCompleted
-
University of HaifaRambam Health Care CampusCompletedParkinson DiseaseIsrael
-
Sheffield Teaching Hospitals NHS Foundation TrustRecruitingMolar Incisor HypomineralisationUnited Kingdom
-
The University of Texas Health Science Center,...CompletedWound InfectionUnited States
-
University of Texas at AustinEnrolling by invitation